Abacavir and Riociguat: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Abacavir-associated CYP1A1 inhibition can increase riociguat exposure.
Clinical significance and safety
Increased riociguat exposure was reported with fixed-dose abacavir/dolutegravir/lamivudine. This may increase riociguat adverse effects, so the prescriber should review the combination and tolerability. The exact increase is not fully characterized and should not be assumed to be identical in every regimen or patient.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.